Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS


You May Also Like

Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference

Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity ...